
    
      Protocol PLX108-05 is a Phase 1/2 open-label, sequential dose escalation (Part 1) followed by
      cohort expansion (Part 2) design at the recommended phase 2 dose established in Part 1 (i.e.
      3,000 mg/day). Treatment with PLX3397 will consist of continuous oral administration in
      28-day cycles until unacceptable or dose-limiting toxicity, disease progression or relapse,
      patient death, Investigator decision, or voluntary withdrawal.
    
  